Showing results (1-10 of 356) with videos related to
Sort By:
Pageof 36
Hamostaseologie|August 9, 2011
Treatment and secondary prevention of venous thromboembolism in cancer patients. Current strategies and new therapeutic optionsC Ay, I PabingerHamostaseologie|August 9, 2011
Risk of venous thromboembolism and primary prophylaxis in cancer. Should all patients receive thromboprophylaxis?I Pabinger, C AyHamostaseologie|March 6, 2015
VTE risk assessment in cancer. Who needs prophylaxis and who does not?C Ay, I PabingerThrombosis Research|May 11, 2016
PO-01 - Congestive heart failure is an independent risk factor for venous thromboembolism and mortality in cancer patientsO Königsbrügge, J Riedl, E Grilz, et al.Hamostaseologie|July 28, 2011
Clinical significance of circulating microparticles for venous thromboembolism in cancer patientsJ Thaler, C Ay, I PabingerAnnals of Oncology : Official Journal of the European Society for Medical Oncology|March 29, 2019
Treatment of cancer-associated venous thromboembolism in the age of direct oral anticoagulantsC Ay, J Beyer-Westendorf, I PabingerThrombosis Research|May 11, 2016
PO-63 - Exhausted platelets in cancer patients with high risk of venous thromboembolism and poor prognosisJ Riedl, A Kaider, C Marosi, et al.Journal of Thrombosis and Haemostasis : JTH|December 23, 2014
Estimating risk of venous thromboembolism in patients with cancer in the presence of competing mortalityC Ay, F Posch, A Kaider, et al.Journal of Thrombosis and Haemostasis : JTH|April 21, 2018
Combination of isocitrate dehydrogenase 1 (IDH1) mutation and podoplanin expression in brain tumors identifies patients at high or low risk of venous thromboembolismP Mir Seyed Nazari, J Riedl, M Preusser, et al.Pageof 36